Metformin prevents the development of chronic heart failure in the SHHF rat model

Diabetes

Volumn 61, Issue 4, 2012, Pages 944-953

  Cittadini, Antonio ^a   Napoli, Raffaele ^a   Monti, Maria Gaia ^a   Rea, Domenica ^a   Longobardi, Salvatore ^b   Netti, Paolo Antonio ^a,c   Walser, Marion ^d   Samà, Mariateresa ^e   Aimaretti, Gianluca ^e   Isgaard, Jörgen ^d   Saccà, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Merck Serono Group   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAT DROPLET; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; METFORMIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; BIOMECHANICS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; FIBROSIS; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PERFUSION; HEART PROTECTION; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOLOGY; INSULIN RESISTANCE; LIPID STORAGE; LONG TERM CARE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HEART FAILURE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VENTRICULAR REMODELING;

EID: 84859534676     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1132     Document Type: Article

References (44)

1. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334-341 (Pubitemid 41043777)
2. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000;21:1368-1375 (Pubitemid 30599132)
3. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-1026 (Pubitemid 41316509)
4. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004;61:297-306 (Pubitemid 38091770)
5. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-448 (Pubitemid 47196549)
6. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51: 93-102
7. Saccà L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail 2009;2:151-156
8. Saccà L, Napoli R. Insulin resistance in chronic heart failure: a difficult bull to take by the horns. Nutr Metab Cardiovasc Dis 2009;19:303-305
9. Cohen D. Rosiglitazone: what went wrong? BMJ 2010;341:c4848
10. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111: 583-590 (Pubitemid 40216485)
11. Bertrand L, Ginion A, Beauloye C, et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 2006;291:H239-H250
12. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-2351 (Pubitemid 41384275)
13. Evans JM, Doney AS, AlZadjali MA, et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010;106:1006-1010
14. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care 2007;30:e129
15. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403-411
16. Sasaki H, Asanuma H, Fujita M, et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009;119:2568-2577
17. Forcheron F, Basset A, Abdallah P, Del Carmine P, Gadot N, Beylot M. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model-the Zucker diabetic rat. Cardiovasc Diabetol 2009;8:16
18. Wang XF, Zhang JY, Li L, Zhao XY, Tao HL, Zhang L. Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol 2011;38:94-101
19. Heyen JR, Blasi ER, Nikula K, et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 2002;283:H1775-H1784 (Pubitemid 35217010)
20. Cittadini A, Isgaard J, Monti MG, et al. Growth hormone prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41: 2154-2163 (Pubitemid 36733540)
21. Strömer H, Cittadini A, Szymanska G, Apstein CS, Morgan JP. Validation of different methods to compare isovolumic cardiac function in isolated hearts of varying sizes. Am J Physiol 1997;272:H501-H510
22. Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism 2000;49:467-472 (Pubitemid 30196572)
23. Bogazzi F, Russo D, Raggi F, et al. Transgenic mice overexpressing growth hormone (GH) have reduced or increased cardiac apoptosis through activation of multiple GH-dependent or -independent cell death pathways. Endocrinology 2008;149:5758-5769
24. Axelsen LN, Lademann JB, Petersen JS, et al. Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation. Am J Physiol Regul Integr Comp Physiol 2010;298:R1560-R1570
25. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33 (Pubitemid 34705373)
26. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 2011;90:224-233
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
28. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007;116:1170-1175 (Pubitemid 47360218)
29. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000;97:1784-1789 (Pubitemid 30118520)
30. Chiu H-C, Kovacs A, Ford DA, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001;107:813-822 (Pubitemid 32274034)
31. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129 (Pubitemid 40894649)
32. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 2008;368:402-407
33. Yoon Y-S, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073-2085 (Pubitemid 40577902)
34. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? Heart 2001;86:368-372 (Pubitemid 32889367)
35. Katakam PV, Ujhelyi MR, Hoenig M, Miller AW. Metformin improves vascular function in insulin-resistant rats. Hypertension 2000;35:108-112 (Pubitemid 30054245)
36. Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev 2009;14:213-224
37. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005;66:444-453 (Pubitemid 40725756)
38. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci U S A 2003;100:4891-4896 (Pubitemid 36457824)
39. Shoghi KI, Finck BN, Schechtman KB, et al. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging 2009; 2:373-381
40. Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Arch Biochem Biophys 2008;477:86-91
41. Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S. Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague-Dawley rats. PPAR Res. 2009;2009:237865
42. Goltsman I, Wang X, LaVallie ER, et al. Effects of chronic rosiglitazone treatment in renal handling of salt and water in rats with volume-overload congestive heart failure. Cir Heart Fail 2011;4:345-354
43. Kravchuk E, Grineva E, Bairamov MG, Galagudza M, Vlasov T. The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type II. Exp Diab Res 2011;2011: 907496
44. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 2003; 58:632-637 (Pubitemid 36700421)